Press Releases from DelveInsight Business Research LLP (2397 total)
Progressive Supranuclear Palsy Pipeline Analysis (2023) Covering Clinical Trials …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Progressive Supranuclear Palsy therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Progressive Supranuclear Palsy Pipeline Insight,…
Myotonic Dystrophy Pipeline Analysis (2023) Covering Clinical Trials, Emerging T …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 20+ key pharma and biotech companies are working on 22+ pipeline drugs in the Myotonic Dystrophy therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Myotonic Dystrophy Pipeline Insight, 2023" report…
Gonorrhea Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 12+ key pharma and biotech companies are working on 12+ pipeline drugs in the Gonorrhea therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Gonorrhea Pipeline Insight, 2023" report by DelveInsight…
Carcinoid Syndrome Pipeline Analysis (2023) Covering Clinical Trials, Emerging T …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, several major pharma and biotech companies are working on various pipeline therapies in the Carcinoid Syndrome therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Carcinoid Syndrome Pipeline Insight, 2023" report by…
Open-Angle Glaucoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 20+ key pharma and biotech companies are working on 20+ pipeline drugs in the Open-Angle Glaucoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Open-Angle Glaucoma Pipeline Insight, 2023" report…
Schistosomiasis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Ther …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, several major pharma and biotech companies are working on developing various pipeline therapies in the Schistosomiasis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Schistosomiasis Pipeline Insight, 2023" report by DelveInsight…
Pancreatic Ductal Adenocarcinoma (PDAC) Pipeline Analysis (2023) Covering Clinic …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 80+ key pharma and biotech companies are working on 80+ pipeline drugs in the Pancreatic Ductal Adenocarcinoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Pancreatic Ductal Adenocarcinoma Pipeline Insight,…
Pancreatic Ductal Adenocarcinoma (PDAC) Pipeline Analysis (2023) Covering Clinic …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 80+ key pharma and biotech companies are working on 80+ pipeline drugs in the Pancreatic Ductal Adenocarcinoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Pancreatic Ductal Adenocarcinoma Pipeline Insight,…
Pancreatic Cancer Pipeline Analysis (2023) Covering Clinical Trials, Emerging Th …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 290+ key pharma and biotech companies are working on 300+ pipeline drugs in the Pancreatic Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Pancreatic Cancer Pipeline Insight, 2023" report…
Myasthenia Gravis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Th …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, about 20+ key pharma and biotech companies are working on 20+ pipeline drugs in the Myasthenia Gravis therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Myasthenia Gravis Pipeline Insight, 2023" report by…
Gallbladder Cancer Market to Witness Growth by 2032 | Celgene, MedImmune, Ohara …
DelveInsight's "Gallbladder Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Gallbladder Cancer, historical and forecasted epidemiology as well as the Gallbladder Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Gallbladder Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Gallbladder Cancer market size…
ESR1-Mutated Metastatic Breast Cancer Market to Witness Growth by 2032 | Arvinas …
DelveInsight's "ESR1-Mutated Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of ESR1-Mutated Metastatic Breast Cancer, historical and forecasted epidemiology as well as the ESR1-Mutated Metastatic Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The ESR1-Mutated Metastatic Breast Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and…
Ependymoma Market to Witness Growth by 2032, asserts DelveInsight | Fera Pharmac …
DelveInsight's "Ependymoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Ependymoma, historical and forecasted epidemiology as well as the Ependymoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Ependymoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Ependymoma market size from 2019 to 2032, segmented…
Common Warts Market to Witness Growth by 2032 | Nielsen BioSciences, Veloce BioP …
DelveInsight's "Common Warts Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Common Warts, historical and forecasted epidemiology as well as the Common Warts market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Common Warts market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Common Warts market size…
Chronic Liver Disease Market to Witness Growth by 2032 | Astellas Pharma, Bristo …
DelveInsight's "Chronic Liver Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Liver Disease, historical and forecasted epidemiology as well as the Chronic Liver Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chronic Liver Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted…
Methicillin Resistant Staphylococcus Aureus Pipeline, Clinical Trials Studies, E …
DelveInsight's, "Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Insight 2023" report provides comprehensive insights about 25+ companies and 27+ pipeline drugs in Methicillin-Resistant Staphylococcus Aureus Infections pipeline landscape. It covers the Methicillin Resistant Staphylococcus Aureus pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Methicillin Resistant Staphylococcus Aureus pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products…
Nosocomial Pneumonia Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers …
DelveInsight's, "Nosocomial Pneumonia Pipeline Insight, 2023," report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in the Nosocomial Pneumonia pipeline landscape. It covers the Nosocomial Pneumonia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Nosocomial Pneumonia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the…
Eosinophilic Esophagitis Pipeline, FDA Approvals, Clinical Trials Studies, and L …
DelveInsight's, "Eosinophilic Esophagitis Pipeline Insight 2023" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Eosinophilic Esophagitis pipeline landscape. It covers the Eosinophilic Esophagitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Eosinophilic Esophagitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the…
Oral Mucositis Pipeline, FDA Approvals, Clinical Trials Developments and Compani …
(Albany, United States) As per DelveInsight's assessment, globally, the Oral Mucositis Pipeline constitutes 10+ Oral Mucositis companies continuously working towards developing 10+ Oral Mucositis Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
To explore more information on the latest breakthroughs in the Oral Mucositis Pipeline treatment landscape of the report, click here @ Oral Mucositis Pipeline Outlook- https://www.delveinsight.com/report-store/oral-mucositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
…
Follicular Lymphoma Pipeline, FDA Approvals, Clinical Trials Developments and Co …
DelveInsight's, "Follicular Lymphoma Pipeline Insight 2023" report provides comprehensive insights about 50+ Follicular Lymphoma companies and 50+ pipeline drugs in the Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Moderate to Severe Inflammatory Acne Vulgaris Pipeline, FDA Approvals, Clinical …
DelveInsight's, "Moderate to Severe Inflammatory Acne Vulgaris Pipeline Insight 2023" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Moderate to Severe Inflammatory Acne Vulgaris pipeline landscape. It covers the Moderate to Severe Inflammatory Acne Vulgaris Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Moderate to Severe Inflammatory Acne Vulgaris pipeline therapeutics assessment by product type, stage, route of administration, and…
C-MET Non-Small Cell Lung Cancer Pipeline, FDA Approvals, Clinical Trials Develo …
DelveInsight's, "C-MET Non-Small Cell Lung Cancer (C-MET+ NSCLC) - Pipeline Insight, 2023," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the C-MET Non-Small Cell Lung Cancer pipeline landscape. It covers the C-MET Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the C-MET Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule…
Adrenoleukodystrophy Pipeline, FDA Approvals, Clinical Trials Developments and C …
DelveInsight's, "Adrenoleukodystrophy Pipeline Insight, 2023," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Adrenoleukodystrophy pipeline landscape. It covers the Adrenoleukodystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Adrenoleukodystrophy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Adrenoleukodystrophy Pipeline Report
• DelveInsight's Adrenoleukodystrophy…
NK Cell Therapy Pipeline, FDA Approvals, Clinical Trials Developments and Compan …
DelveInsight's, "NK Cell Therapy Pipeline Insight 2023" report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NK Cell Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
…
Behçet's Disease Pipeline, FDA Approvals, Clinical Trials Developments and Comp …
DelveInsight's, "Behçet's Disease Pipeline Insight 2023" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Behçet's Disease pipeline landscape. It covers Behçet's Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers Behçet's Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Behçet's Disease Pipeline…
Hypoglycemia Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapi …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 5+ key pharma and biotech companies are working on 5+ pipeline drugs in the Hypoglycemia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Hypoglycemia Pipeline Insight, 2023" report by DelveInsight…
Postoperative Pain Pipeline Analysis (2023) Covering Clinical Trials, Emerging T …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 45+ key pharma and biotech companies are working on 50+ pipeline drugs in the Postoperative Pain therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Postoperative Pain Pipeline Insight, 2023" report…
Influenza Virus B Infections Pipeline Analysis (2023) Covering Clinical Trials, …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Influenza Virus B Infections therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Influenza Virus B Infections…
Renal Anemia Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapi …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 20+ key pharma and biotech companies are working on 20+ pipeline drugs in the Renal Anemia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Renal Anemia Pipeline Insight, 2023" report…
Non-Alcoholic Fatty Liver Disease (NAFLD) Pipeline Analysis (2023) Covering Clin …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 110+ key pharma and biotech companies are working on 160+ pipeline drugs in the Non-Alcoholic Fatty Liver Disease (NAFLD) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Non-Alcoholic Fatty Liver…
Lung Adenocarcinoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 25+ key pharma and biotech companies are working on 25+ pipeline drugs in the Lung Adenocarcinoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Lung Adenocarcinoma Pipeline Insight, 2023" report…
Glomerulonephritis Pipeline Analysis (2023) Covering Clinical Trials, Emerging T …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, several major pharma and biotech companies are working on various pipeline therapies in the Glomerulonephritis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Glomerulonephritis Pipeline Insight, 2023" report by DelveInsight provides…
HER2 Negative Metastatic Breast Cancer Pipeline Analysis (2023) Covering Clinica …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the HER2 Negative Metastatic Breast Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"HER2 Negative Metastatic…
Non-Small Cell Lung Cancer (NSCLC) Pipeline Analysis (2023) Covering Clinical Tr …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 135+ key pharma and biotech companies are working on 150+ pipeline drugs in the Non-Small Cell Lung Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Non-Small Cell Lung Cancer…
Hypertension Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapi …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 100+ key pharma and biotech companies are working on 100+ pipeline drugs in the Hypertension therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Hypertension Pipeline Insight, 2023" report by DelveInsight…
Myositis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 202 …
DelveInsight's, "Myositis Pipeline Insight 2023," report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Myositis pipeline landscape. It covers the Myositis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myositis Pipeline Report
• DelveInsight's Myositis pipeline report…
Constipation Pipeline, FDA Approvals, Clinical Trials Developments and Companies …
DelveInsight's, "Constipation Pipeline Insight 2023" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Constipation pipeline landscape. It covers the Constipation pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Constipation pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Constipation Pipeline Report
• DelveInsight's Constipation…
Alpha-1 Antitrypsin Deficiency Pipeline, FDA Approvals, Clinical Trials Developm …
DelveInsight's, "Alpha1-Antitrypsin Deficiency Pipeline Insight 2023" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Alpha1-Antitrypsin Deficiency pipeline landscape. It covers the Alpha-1 Antitrypsin Deficiency pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Alpha-1 Antitrypsin Deficiency pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Cirrhosis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 20 …
DelveInsight's, "Cirrhosis Pipeline Insight, 2023," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Cirrhosis pipeline landscape. It covers the Cirrhosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Cirrhosis Pipeline Report
• DelveInsight's Cirrhosis pipeline report…
Crohn's Disease Pipeline, FDA Approvals, Clinical Trials Developments and Compan …
DelveInsight's, "Crohn's Disease Pipeline Insight, 2023," report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn's Disease pipeline landscape. It covers the Crohn's Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Crohn's Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Crohn's…
Post-Polycythemia Vera Myelofibrosis Pipeline Analysis (2023) Covering Clinical …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 17+ key pharma and biotech companies are working on 17+ pipeline drugs in the Post-Polycythemia Vera Myelofibrosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Post-Polycythemia Vera Myelofibrosis Pipeline Insight,…
Overactive Bladder Pipeline Analysis (2023) Covering Clinical Trials, Emerging T …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Overactive Bladder therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Overactive Bladder Pipeline Insight, 2023" report…
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Pipeline Analysis (2023) Cover …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 13+ key pharma and biotech companies are working on 13+ pipeline drugs in the Chemotherapy-Induced Peripheral Neuropathy (CIPN) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Chemotherapy-Induced Peripheral Neuropathy (CIPN)…
Synovial Sarcoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging The …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 14+ key pharma and biotech companies are working on 14+ pipeline drugs in the Synovial Sarcoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Synovial Sarcoma Pipeline Insight, 2023" report…
Chronic Hepatitis B Virus Pipeline Analysis (2023) Covering Clinical Trials, Eme …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Chronic Hepatitis B Virus therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Chronic Hepatitis B Virus…
Atopic Dermatitis Pipeline, FDA Approvals, Clinical Trials Developments and Comp …
DelveInsight's, "Atopic Dermatitis Pipeline Insight 2023" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the Atopic Dermatitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atopic Dermatitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the…
Guillain-Barre Syndrome Pipeline Analysis (2023) Covering Clinical Trials, Emerg …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, several major pharma and biotech companies are working on various pipeline therapies in the Guillain-Barre Syndrome (GBS) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Guillain-Barre Syndrome (GBS) Pipeline Insight, 2023"…
Relapsed Or Refractory Myelodysplastic Syndrome Pipeline Analysis (2023) Coverin …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, several major pharma and biotech companies are working on various pipeline therapies in the Relapsed Or Refractory Myelodysplastic Syndrome therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Relapsed Or Refractory Myelodysplastic…
Candidemia Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, several major pharma and biotech companies are working on various pipeline therapies in the Candidemia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Candidemia Pipeline Insight, 2023" report by DelveInsight provides…
Metastatic Urothelial Carcinoma Pipeline Analysis (2023) Covering Clinical Trial …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 40+ key pharma and biotech companies are working on 40+ pipeline drugs in the Metastatic Urothelial Carcinoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Metastatic Urothelial Carcinoma Pipeline Insight,…
